Dr. Antje Kroner-Milsch
The overarching goal of my laboratory is to improve the quality of life and health of persons living with spinal cord injury (SCI). To achieve this goal, our work focuses on targeted control of the secondary tissue damage. Primary tissue damage, most often caused by a mechanical impact, is significantly worsened by multiple secondary processes, which include inflammation and hemorrhage. Current research in my lab is focused on tissue protection after SCI by interrupting hemorrhage induced and inflammatory processes which directly promote tissue damage and neuronal death and result in impaired functional outcome.
One research focus of my lab is the targeted inhibition of pro-inflammatory factors. This approach aims to specifically inhibit harmful, prolonged, and exacerbated inflammation, while maintaining the essential and tissue protective inflammatory processes. Previous experiments have shown the importance of pro-inflammatory factors in mediating inflammatory damage but also directly affecting neuronal survival and function, resulting in impaired recovery. A comprehensive understanding of inflammatory processes after SCI is essential for translational approaches in specifically targeting and inhibiting harmful mediators.
A second focus of my research investigates the role of hemorrhage after SCI. The reactivity of free hemoglobin and its downstream products induces a pronounced inflammatory and tissue toxic response. Interrupting this process will have a significant impact on the tissue preservation and functional outcome.
IL-12p40 promotes secondary damage and functional impairment after spinal cord contusional injury.
(Rosas Almanza J, Stehlik KE, Page JJ, Xiong SH, Tabor EG, Aperi B, Patel K, Kodali R, Kurpad S, Budde MD, Tarima S, Swartz K, Kroner A.) J Neurosci Res. 2022 Dec;100(12):2213-2231 PMID: 36089917 SCOPUS ID: 2-s2.0-85137752150 09/13/2022
Dysregulation of Iron Homeostasis in the Central Nervous System and the Role of Ferroptosis in Neurodegenerative Disorders.
(David S, Jhelum P, Ryan F, Jeong SY, Kroner A.) Antioxid Redox Signal. 2022 Jul;37(1-3):150-170 PMID: 34569265 09/28/2021
Ferroptosis in Neurological Disease.
(David S, Ryan F, Jhelum P, Kroner A.) Neuroscientist. 2022 Jun 08:10738584221100183 PMID: 35678019 06/10/2022
Correction to: CCL3 contributes to secondary damage after spinal cord injury.
(Pelisch N, Almanza JR, Stehlik KE, Aperi BV, Kroner A.) J Neuroinflammation. 2021 Apr 03;18(1):87 PMID: 33812368 PMCID: PMC8019158 04/05/2021
Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.
(Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A.) eNeuro. 2021;8(2) PMID: 33632814 PMCID: PMC7986543 02/27/2021
CCL3 contributes to secondary damage after spinal cord injury.
(Pelisch N, Rosas Almanza J, Stehlik KE, Aperi BV, Kroner A.) J Neuroinflammation. 2020 Nov 27;17(1):362 PMID: 33246483 PMCID: PMC7694914 11/29/2020
Bilateral cervical contusion spinal cord injury: A mouse model to evaluate sensorimotor function.
(Reinhardt DR, Stehlik KE, Satkunendrarajah K, Kroner A.) Exp Neurol. 2020 Sep;331:113381 PMID: 32561411 SCOPUS ID: 2-s2.0-85086575731 06/21/2020
Role of microglia in spinal cord injury.
(Kroner A, Rosas Almanza J.) Neurosci Lett. 2019 Sep 14;709:134370 PMID: 31283964 07/10/2019
Myeloid cell responses after spinal cord injury.
(David S, Kroner A, Greenhalgh AD, Zarruk JG, López-Vales R.) J Neuroimmunol. 2018 Aug 15;321:97-108 PMID: 29957394 06/30/2018
Small-Molecule Stabilization of 14-3-3 Protein-Protein Interactions Stimulates Axon Regeneration.
(Kaplan A, Morquette B, Kroner A, Leong S, Madwar C, Sanz R, Banerjee SL, Antel J, Bisson N, David S, Fournier AE.) Neuron. 2017 Mar 08;93(5):1082-1093.e5 PMID: 28279353 03/11/2017
Arginase-1 is expressed exclusively by infiltrating myeloid cells in CNS injury and disease.
(Greenhalgh AD, Passos Dos Santos R, Zarruk JG, Salmon CK, Kroner A, David S.) Brain Behav Immun. 2016 Aug;56:61-7 PMID: 27126514 04/30/2016
Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.
(Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.) G3 (Bethesda). 2016 Jul 07;6(7):2073-9 PMID: 27194806 PMCID: PMC4938660 05/20/2016